(NASDAQ: TYRA) Tyra Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Tyra Biosciences's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast TYRA's revenue for 2027 to be $1,000,387,318, with the lowest TYRA revenue forecast at $961,480,406, and the highest TYRA revenue forecast at $1,039,294,230. On average, 4 Wall Street analysts forecast TYRA's revenue for 2028 to be $5,131,288,748, with the lowest TYRA revenue forecast at $3,067,783,378, and the highest TYRA revenue forecast at $9,341,389,728.
In 2029, TYRA is forecast to generate $14,082,010,439 in revenue, with the lowest revenue forecast at $7,537,814,510 and the highest revenue forecast at $28,802,840,399.